[{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"University of Arizona","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Arizona \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"University of Arizona \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sunnybrook Health Sciences Centre \/ Unity Health Toronto","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ Unity Health Toronto"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"AMAG Pharmaceuticals | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ AMAG Pharmaceuticals | Oregon Health and Science University","highestDevelopmentStatusID":"8","companyTruncated":"OHSU Knight Cancer Institute \/ AMAG Pharmaceuticals | Oregon Health and Science University"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Celgene Corporation | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Celgene Corporation | Oregon Health and Science University","highestDevelopmentStatusID":"8","companyTruncated":"OHSU Knight Cancer Institute \/ Celgene Corporation | Oregon Health and Science University"},{"orgOrder":0,"company":"OHSU Knight Cancer Institute","sponsor":"Merck & Co | Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OHSU Knight Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OHSU Knight Cancer Institute \/ Merck & Co | Oregon Health and Science University","highestDevelopmentStatusID":"8","companyTruncated":"OHSU Knight Cancer Institute \/ Merck & Co | Oregon Health and Science University"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase IV","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Thomas Jefferson University \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Thomas Jefferson University \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Auerbach Hematology Oncology Associates P C","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Auerbach Hematology Oncology Associates P C","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Auerbach Hematology Oncology Associates P C \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Auerbach Hematology Oncology Associates P C \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Auerbach Hematology Oncology Associates P C","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2011","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase III","graph3":"Auerbach Hematology Oncology Associates P C","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Auerbach Hematology Oncology Associates P C \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Auerbach Hematology Oncology Associates P C \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Dialysis Clinic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase IV","graph3":"Dialysis Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dialysis Clinic \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Dialysis Clinic \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.65000000000000002,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Covis Pharma"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.65000000000000002,"dosageForm":"Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Covis Pharma"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2019","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Solution","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Beau Nakamoto","sponsor":"Hawaii Pacific Health | University of Hawaii | National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Beau Nakamoto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beau Nakamoto \/ Hawaii Pacific Health | University of Hawaii | National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"8","companyTruncated":"Beau Nakamoto \/ Hawaii Pacific Health | University of Hawaii | National Institute of Neurological Disorders and Stroke"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Christopher J Chermansky","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Urology","graph2":"Phase I","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipella Pharmaceuticals \/ Christopher J Chermansky","highestDevelopmentStatusID":"6","companyTruncated":"Lipella Pharmaceuticals \/ Christopher J Chermansky"}]
Find Clinical Drug Pipeline Developments & Deals for Ferumoxytol
Details :
Ferumoxytol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cystitis, Interstitial.
Details :
The acquisition adds AMAG's key products Feraheme®, Makena® and Ciraparantag to Covis' pipeline as it carries out its mission of expanding patient access to much needed therapies.
Details :
With this deal, Covis gains access to AMAG’s two commercial therapies, Makena, indicated for women with risk of preterm birth in singleton pregnancies and Feraheme indicated treat iron deficiency anaemia in CKD patients and for whom oral iron is not su...
Details :
Ferumoxytol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.
Details :
Ferumoxytol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia, Iron-Deficiency.
Details :
Ferumoxytol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Anemia.
Details :
Ferumoxytol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency.
Details :
Ferumoxytol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Post-Bariatric, Anemia, Iron-Deficiency.
Details :
Ferumoxytol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia, Iron-Deficiency-associated with Pregnancy.
Details :
Ferumoxytol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia-associated with Renal Insufficiency, Chronic.
Reset All
